{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:53:10Z","timestamp":1782132790292,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Guidance Project of Science and Technology Commission of Shanghai Municipality","award":["19411962300"],"award-info":[{"award-number":["19411962300"]}]},{"name":"Special clinical research project of Health Commission of Shanghai Municipal","award":["201940400"],"award-info":[{"award-number":["201940400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increasing evidences have revealed the tumor immune microenvironment not only has vital impacts on the origin, progression, and metastasis of tumors significantly but also influences the response to immunotherapy. Nonetheless, to date, the well-rounded expression pattern of immune-related genes in cutaneous melanoma and the comprehensive characterization of tumor immune microenvironment remain not clearly elucidated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We comprehensively evaluated the well-rounded expression pattern of immune-related genes of 686 patients with cutaneous melanoma based on immune-related genes with prognostic value and systematically correlated the expression pattern of these genes with the comprehensive characterization of tumor immune microenvironment. The IRGscore was constructed to quantify immunological function of individual using principal component analysis algorithms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>Three distinct immune subtypes were determined with obvious survival differences. Melanoma patients\u00a0with high IRGscore was characterized by comprehensive suppression of immune function, showing much poorer prognosis and efficacy for immunotherapy, while the low IRGscore means the robust activation of immune function and the better effect of immunotherapy, which may be responsible for a better prognosis. Besides, the prognostic ability of IRGscore was further validated by the independent dataset of stomach cancers. Furthermore, the predictive effect of immunotherapeutic benefits of IRGscore was demonstrated by the independent dataset of melanoma patients accepting immunotherapy and another predictive model for immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IRGscore could serve as an independent immunotherapeutic and prognostic predictor, thereby facilitating the identification of appropriate candidates with cutaneous melanoma for immunotherapy and the formulation of individualized therapeutic approaches.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-022-02767-z","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T14:16:41Z","timestamp":1663856201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Dong","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"2767_CR1","doi-asserted-by":"crossref","unstructured":"Kasakovski D, Skrygan M, Gambichler T, Susok L. Advances in targeting cutaneous melanoma. Cancers (Basel). 2021;13(9): 2090.","DOI":"10.3390\/cancers13092090"},{"key":"2767_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","volume":"355","author":"AJ Miller","year":"2006","unstructured":"Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51\u201365.","journal-title":"N Engl J Med"},{"key":"2767_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1056\/NEJMsb2019760","volume":"384","author":"HG Welch","year":"2021","unstructured":"Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med. 2021;384:72\u20139.","journal-title":"N Engl J Med"},{"key":"2767_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392:971\u201384.","journal-title":"Lancet"},{"key":"2767_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"2767_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"2767_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37:318\u201327.","journal-title":"J Clin Oncol"},{"key":"2767_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/med.21727","volume":"41","author":"MA Hossain","year":"2021","unstructured":"Hossain MA, Liu G, Dai B, Si Y, Yang Q, Wazir J, et al. Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Med Res Rev. 2021;41:156\u2013201.","journal-title":"Med Res Rev"},{"key":"2767_CR9","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27:1482\u201392.","journal-title":"Ann Oncol"},{"key":"2767_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18:842\u201359.","journal-title":"Cell Mol Immunol"},{"key":"2767_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pathol.2015.12.006","volume":"48","author":"N Lee","year":"2016","unstructured":"Lee N, Zakka LR, Mihm MC Jr, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016;48:177\u201387.","journal-title":"Pathology"},{"key":"2767_CR12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","volume":"11","author":"F Maibach","year":"2020","unstructured":"Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 2020;11:2105.","journal-title":"Front Immunol"},{"key":"2767_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.omtn.2020.08.030","volume":"22","author":"X Zhang","year":"2020","unstructured":"Zhang X, Shi M, Chen T, Zhang B. Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy. Mol Ther Nucleic Acids. 2020;22:298\u2013309.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2767_CR14","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"2767_CR15","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1111\/jdv.16784","volume":"35","author":"S Osella-Abate","year":"2021","unstructured":"Osella-Abate S, Vignale C, Annaratone L, Nocifora A, Bertero L, Castellano I, et al. Microenvironment in cutaneous melanomas: a gene expression profile study may explain the role of histological regression. J Eur Acad Dermatol Venereol. 2021;35:e35\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2767_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"2767_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662\u201380.","journal-title":"Nat Rev Cancer"},{"key":"2767_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2020.10.019","volume":"433","author":"M Horii","year":"2021","unstructured":"Horii M, Matsushita T. Regulatory B cells and T cell regulation in cancer. J Mol Biol. 2021;433:166685.","journal-title":"J Mol Biol"},{"key":"2767_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.pathol.2019.04.001","volume":"51","author":"S Osella-Abate","year":"2019","unstructured":"Osella-Abate S, Conti L, Annaratone L, Senetta R, Bertero L, Licciardello M, et al. Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma. Pathology. 2019;51:487\u201393.","journal-title":"Pathology"},{"key":"2767_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109\u201318.","journal-title":"Cell Res"},{"key":"2767_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol. 2020;11:583084.","journal-title":"Front Immunol"},{"key":"2767_CR22","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1002\/jcp.30139","volume":"236","author":"Y Chen","year":"2021","unstructured":"Chen Y, Jin H, Song Y, Huang T, Cao J, Tang Q, et al. Targeting tumor-associated macrophages: a potential treatment for solid tumors. J Cell Physiol. 2021;236:3445\u201365.","journal-title":"J Cell Physiol"},{"key":"2767_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12026-014-8516-1","volume":"58","author":"S Bhattacharya","year":"2014","unstructured":"Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58:234\u20139.","journal-title":"Immunol Res"},{"key":"2767_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284\u20137.","journal-title":"Omics"},{"key":"2767_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"2767_CR26","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-20-4107","volume":"81","author":"Q Lan","year":"2021","unstructured":"Lan Q, Liu PY, Bell JL, Wang JY, H\u00fcttelmaier S, Zhang XD, et al. The emerging roles of RNA m(6) A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance. Cancer Res. 2021;81:3431\u201340.","journal-title":"Cancer Res"},{"key":"2767_CR27","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.18632\/aging.202486","volume":"13","author":"Y Liu","year":"2021","unstructured":"Liu Y, Liu N, Liu Q. Constructing a ceRNA-immunoregulatory network associated with the development and prognosis of human atherosclerosis through weighted gene co-expression network analysis. Aging (Albany NY). 2021;13:3080\u2013100.","journal-title":"Aging (Albany NY)"},{"key":"2767_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","volume":"7","author":"D Zeng","year":"2019","unstructured":"Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7:737\u201350.","journal-title":"Cancer Immunol Res"},{"key":"2767_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248\u201362.","journal-title":"Cell Rep"},{"key":"2767_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.594112","volume":"8","author":"S Xu","year":"2020","unstructured":"Xu S, Tang L, Dai G, Luo C, Liu Z. Expression of m6A regulators correlated with immune microenvironment predicts therapeutic efficacy and prognosis in gliomas. Front Cell Dev Biol. 2020;8:594112.","journal-title":"Front Cell Dev Biol"},{"key":"2767_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/clr.13686","volume":"32","author":"BP Jonker","year":"2021","unstructured":"Jonker BP, Gil A, Naenni N, Jung RE, Wolvius EB, Pijpe J. Soft tissue contour and radiographic evaluation of ridge preservation in early implant placement: a randomized controlled clinical trial. Clin Oral Implants Res. 2021;32:123\u201333.","journal-title":"Clin Oral Implants Res"},{"key":"2767_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373.","journal-title":"Cancer Cell"},{"key":"2767_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-020-01170-0","volume":"19","author":"B Zhang","year":"2020","unstructured":"Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m(6) A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020;19:53.","journal-title":"Mol Cancer"},{"key":"2767_CR34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/cas.14730","volume":"112","author":"K Sakai","year":"2021","unstructured":"Sakai K, Tsuboi M, Kenmotsu H, Yamanaka T, Takahashi T, Goto K, et al. Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). Cancer Sci. 2021;112:388\u201396.","journal-title":"Cancer Sci"},{"key":"2767_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","volume":"25","author":"S Singh","year":"2020","unstructured":"Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25:223\u20139.","journal-title":"Drug Discov Today"},{"key":"2767_CR36","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","volume":"11","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, Meylan M, de Reyni\u00e8s A, Saut\u00e8s-Fridman C, Fridman WH. The Tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784.","journal-title":"Front Immunol"},{"key":"2767_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110873","volume":"132","author":"B Lin","year":"2020","unstructured":"Lin B, Du L, Li H, Zhu X, Cui L, Li X. Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully. Biomed Pharmacother. 2020;132:110873.","journal-title":"Biomed Pharmacother"},{"key":"2767_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/CMR.0000000000000515","volume":"29","author":"N Dabrosin","year":"2019","unstructured":"Dabrosin N, Sloth Juul K, B\u00e6hr Georgsen J, Andrup S, Schmidt H, Steiniche T, et al. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status. Melanoma Res. 2019;29:30\u20137.","journal-title":"Melanoma Res"},{"key":"2767_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138.","journal-title":"Cancer Lett"},{"key":"2767_CR40","doi-asserted-by":"publisher","first-page":"R246","DOI":"10.1016\/j.cub.2020.01.031","volume":"30","author":"L Cassetta","year":"2020","unstructured":"Cassetta L, Pollard JW. Tumor-associated macrophages. Curr Biol. 2020;30:R246\u2013r248.","journal-title":"Curr Biol"},{"key":"2767_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44\u201356.","journal-title":"Ann Oncol"},{"key":"2767_CR42","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","volume":"15","author":"LM Sholl","year":"2020","unstructured":"Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer pathology committee. J Thorac Oncol. 2020;15:1409\u201324.","journal-title":"J Thorac Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-022-02767-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T14:19:10Z","timestamp":1663856350000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-022-02767-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2767"],"URL":"https:\/\/doi.org\/10.1186\/s12957-022-02767-z","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"30 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}